Transcutaneous Electrical Muscle Stimulation In Chronic Obstructive Pulmonary Disease (COPD)

Not Applicable

Completed

• Conditions: Chronic Obstructive Pulmonary Disease

• Registration Number: NCT01226342
• Lead Sponsor: The University Clinic of Pulmonary and Allergic Diseases Golnik

Brief Summary

Transcutaneous electrical muscle stimulation (TCEMS) is well established intervention for rehabilitation of clinically stable patients with chronic obstructive pulmonary disease.

The investigators have conceived this study to test whether TCEMS is feasible and tolerated by patients experiencing severe physical and psychical challenge of acutely exacerbated COPD.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-01
• Primary Completion: 2009-06
• Study Completion: 2009-10
• Study First Submitted: 2010-10-18
• Study First Submitted QC: 2010-10-21
• Study First Posted: 2010-10-22
• Status Verified: 2013-04
• Last Update Submitted: 2013-04-10
• Last Update Posted: 2013-04-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• chronic obstructive pulmonary disease GOLD stage III or IV
• acute exacerbation of the disease

Exclusion Criteria

• contraindications for transcutaneous electrical muscle stimulation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Scores on the feasibility scale	10 days (avarage time from admission to discharge)	Patients will be followed from admission until discharge

Secondary Outcome Measures

Name	Time	Method
Scores on the patient satisfaction scale	10 days (avarage time from admission to discharge)	Patients will be followed from admission until discharge
Number of patients with adverse events as a measure of Safety and tolerability	10 days (avarage time from admission to discharge)	Patients will be followed from admission until discharge
Health related quality of life on the St. George respiratory questionnaire	10 days (avarage time from admission to discharge)	Patients will be followed from admission until discharge
Dyspnea on the MRC dyspnea scale	10 days (avarage time from admission to discharge)	Patients will be followed from admission until discharge
Patient symptom scores on the Functional assessment of chronic illness therapy questionaire	10 days (avarage time from admission to discharge)	Patients will be followed from admission until discharge

Trial Locations

Locations (1)

University Clinic Golnik; 🇸🇮 Golnik, Slovenia